Low Libido in Women: Naming an Overlooked Condition
Low libido in women is common yet rarely discussed openly. When a persistent lack of sexual desire causes personal distress or relationship strain, doctors may diagnose Hypoactive Sexual Desire Disorder (HSDD). It is particularly frequent in peri‑ and post‑menopausal women, who represent around 10% of the population, and an estimated 10% of these women are affected by HSDD. Despite this, female sexual health therapy lags far behind options available to men, due to stigma around female desire, limited research funding and discomfort among both patients and healthcare providers in raising sexual concerns. Many women are left wondering whether low interest in sex is simply something they must “accept with age,” instead of a treatable health issue. As international regulators highlight the importance of better treatments for HSDD, attention is finally turning to female testosterone treatment as a targeted option for those whose quality of life is significantly affected.
What Is the Patchless Patch Testosterone Treatment for Women?
Australian pharmaceutical company Acrux has developed a novel female testosterone treatment that uses its proprietary Patchless Patch delivery technology. Rather than a traditional sticky patch, cream or gel, this system acts as a “patchless patch,” delivering hormone through the skin with good evidence of absorption while avoiding the need to rub products on with the hands. Testosterone occurs naturally in both women and men, but at lower levels in women. Leading HSDD expert Dr Susan Davis notes that, when dosed to keep blood levels within the normal range for pre‑menopausal women, testosterone therapy can improve sexual desire, arousal, orgasm, sexual self‑image and reduce distress in post‑menopausal women with HSDD. Acrux has previously used the same Patchless Patch technology in estrogen products such as Evamist and Lenzetto, suggesting women may gain a discreet, precise and easy‑to‑use testosterone patch for women if trials continue to succeed.
From Phase I and II Trials to Global Phase III Ambitions
Acrux has completed Phase I and II clinical trials of its female testosterone product, key early milestones that focus on safety, how the drug is absorbed and metabolised (pharmacokinetics), and identifying appropriate dosing ranges. Feedback from the US Food and Drug Administration has confirmed that these results provide a valid foundation to move into Phase III, the final and usually largest stage of clinical testing before regulators consider approval. In Phase III, the company plans to assess effectiveness and safety in a broader, more diverse group of women with Hypoactive Sexual Desire Disorder, while refining how the medicine should be used in real‑world practice. Acrux is seeking global co‑development partners with strong expertise in women’s health to help design these trials and, if successful, to commercialise the therapy internationally. This strategy could accelerate access in regions like Southeast Asia, including Malaysia, once regulatory requirements are met.
Why Women’s Sexual Health Still Has a Massive Unmet Need
The emerging Patchless Patch underscores how under‑served women’s sexual health has been. HSDD is one of the most prevalent sexual concerns, yet there are very few tailored treatments. In contrast to the rapid development of therapies for men’s sexual problems, women have faced a combination of social stigma, moralisation of female desire and a tendency to see sexual complaints as secondary to other health issues. Even within religious and ethical debates, some global faith leaders now emphasise that sexual matters should not overshadow broader issues of justice and equality, reflecting a slow shift in how intimate health concerns are prioritised. However, many women still feel embarrassed to talk about low libido with doctors, or fear being dismissed. Addressing this “massive unmet need” requires not only new medicines like female testosterone treatment, but also better education, open conversation and clinical training so women are heard and taken seriously.
Potential Benefits, Risks, and What Malaysian Women Can Do Now
Testosterone-based women sexual health therapy may offer meaningful benefits for some post‑menopausal women with HSDD, including improved desire, arousal and sexual satisfaction. But hormones are powerful and must be used under medical supervision. Excess or inappropriate dosing can lead to side effects such as acne, unwanted hair growth, voice changes or alterations in cholesterol. That is why experts stress avoiding do‑it‑yourself hormone use or unregulated products bought online. For Malaysian women currently struggling with low libido, the best step is to speak with a trusted doctor—ideally a gynaecologist, endocrinologist or sexual health specialist—who can review medications, hormone status, mental health, relationship dynamics and lifestyle factors such as sleep, stress and exercise. Counselling or couples therapy may also help. While the female testosterone Patchless Patch moves through Phase III trials and regulatory review, focusing on holistic care and evidence‑based options can already make a tangible difference.